Insider buying last 90 days
No open-market insider purchases were filed for ERAS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ERAS insider filing, plotted on the chart in Gekko.Open ERAS in Gekko
NASDAQ: ERAS
Erasca (ERAS) Stock Analysis & Forecast
Sep 28 close
$14.13−0.12 (−0.8%)
Gekko Brief
AI summaryErasca stock rose 4.12 percent to $14.52 on September 24 ahead of updated ERAS-0015 trial data scheduled for presentation in November, including monotherapy data from the Phase 1 AURORAS-1 trial and nonclinical combination data for ERAS-0015 and ERAS-4001. Alongside this, several law firms, including Bronstein, Gewirtz & Grossman, Bernstein Liebhard, and Johnson Fistel, have announced investigations into Erasca and its officers and directors concerning potential breaches of fiduciary duty and securities claims tied to purchases made before January 14, 2025.
Shares closed at $14.13, down 0.8%, sitting between the 50-day average of $17.29 and the 200-day average of $13.76, reflecting a mixed trend. The GekkoIndex reads 68.9, placing the stock in the Accumulation zone. Price sits 23% below the Gekko Fair Value of $18.34. Over the past year the stock is up 680.7%, though the past month shows a decline of 27.5% and the past three months a decline of 22.7%.
The next earnings date falls on 11 November 2026, 43 days away and outside a typical 20-trading-day holding window; the prior report on 12 August showed an actual EPS of -0.14 against an estimate of -0.11, with a -2.5% reaction. Seasonality over the next 20 trading days has averaged -0.4% across 5 years, rising in 2 of them. Smart money data shows one trailblazer holder, with no insider, Congress, or unusual options activity recorded in their respective windows. Analyst consensus stands at 6 buy and 2 hold ratings among 8 firms, with a consensus target of $24.11.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Erasca price vs fair value
Close $14.13200-day averageGekko Fair Value $18.34
Erasca quick facts
- Market cap
- $4.90B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.95
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.65
- Volume
- 3.60M avg 4.88M
- 1-year return
- +680.7%
- Typical daily move
- ±7.5%
- Typical 20-day move
- ±12.6%
- 50-day average
- $17.29
- 200-day average
- $13.76
- Next earnings
- Nov 11
- Shares outstanding
- 349.8M
Erasca swing-trade checklist
Erasca scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $14.13 sits between the 50-day ($17.29) and 200-day ($13.76) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
68.9, Accumulation
Reading 68.9 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
23.0% below
Price is 23% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 43 days
Next report Nov 11, 2026, 43 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−0.4% on average
From this point in the calendar, the next 20 trading days averaged −0.4% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Erasca stock chart and price history
Erasca closed at $14.13 on Sep 28, 2026, +680.7% over the past year, inside a 52-week range of $1.79 to $24.28.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −27.5%
- 3 months
- −22.7%
- 6 months
- −5.6%
- 1 year
- +680.7%
The full ERAS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ERAS in Gekko
Follow Erasca through every session
Put ERAS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ERAS in GekkoFree for 7 days. No credit card required.
Erasca GekkoIndex: the smart money zone
Erasca’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.9, in the Accumulation zone, down 1.1 points over five sessions.
68.9Accumulation
Down 1.1 points over five sessions, from the Buying zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 37 | +0.3% | +3.6% | ||
| Accumulation (current zone) | 176 | +3.7% | +9.1% | ||
| Neutral | 389 | +2.3% | +14.0% | ||
| Distribution | 63 | +2.5% | +7.8% | ||
| Selling | 7 | Too few readings yet | |||
Average ERAS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ERAS price, zone by zone.Track ERAS in Gekko
Is Erasca stock overvalued? Gekko Fair Value
Erasca trades 23.0% below Gekko Fair Value of $18.34, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Erasca shares are worth, recalculated every trading day.
$18.34
Gekko Fair Value, Sep 29, 2026
23.0% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ERAS in Gekko
Erasca insider and Congress trading
No open-market insider purchases were filed for Erasca, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ERAS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ERAS, plotted on the chart in Gekko.Open ERAS in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ERAS.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Erasca earnings: next date and track record
Erasca reports on Nov 11, 2026 (43 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 11, 2026
43 days away
- EPS estimate
- −$0.14
3 of 8reports beat the EPS estimate
±6.8%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 12, 2026 | −$0.14 est −$0.11 | — | −2.5% |
| May 11, 2026 | −$0.60 est −$0.23 | — | +2.6% |
| Mar 12, 2026 | −$0.10 est −$0.11 | — | −12.1% |
| Nov 12, 2025 | −$0.11 est −$0.11 | — | +7.6% |
| Aug 12, 2025 | −$0.12 est −$0.12 | — | +9.5% |
| Mar 20, 2025 | −$0.11 est −$0.12 | — | +3.4% |
| Nov 12, 2024 | −$0.11 est −$0.17 | — | −8.4% |
| Aug 12, 2024 | −$0.29 est −$0.18 | — | +8.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Erasca stock forecast and analyst price targets
Analysts’ average 12-month price target for Erasca is $24.11, +70.6% from the last close, from 8 firms rating the stock in the last 90 days.
$24.11consensus 12-month target, +70.6% from the last close
Now $14.13Avg $24.11
Low $20High $33
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 1 | J.P. Morgan | $33 | +133.5% |
| Aug 27 | J.P. Morgan | $33 | +133.5% |
| Aug 26 | Bank of America Securities | $20 | +41.5% |
| Aug 24 | J.P. Morgan | $25 | +76.9% |
| Aug 24 | Bank of America Securities | $20 | +41.5% |
+9.1%average 20-day move after past Accumulation readings
−0.4%average move over the next 20 trading days in the last 5 years
±7.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Erasca seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Erasca averaged −0.4% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.1% | 3 of 5 |
| Next 10 trading days | +4.1% | 3 of 5 |
| Next 15 trading days | +4.9% | 3 of 5 |
| Next 20 trading days | −0.4% | 2 of 5 |
| Next 30 trading days | +4.3% | 3 of 5 |
For scale, ERAS’s typical 20-trading-day move in either direction is about 12.6%.
Erasca market cap and key statistics
Erasca’s market cap is $4.90B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $4.90B
- EPS, TTM
- −$0.95
- Gekko Fair Value
- $18.34
Trading
- Volume
- 3.60M
- Avg volume, 20 days
- 4.88M
- 52-week high
- $24.28
- 52-week low
- $1.79
- Shares outstanding
- 349.8M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -78.2%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.65
- Typical daily move
- ±7.5%
- Typical 20-day move
- ±12.6%
Erasca stock news this week
Coverage of Erasca this week reads negative: 1 positive, 0 neutral and 3 negative headlines.
- Erasca stock gains 4.12 percent ahead of trial dataAD HOC NEWS, Sep 25
- Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) Investors to Inquire about Securities InvestigationACCESS Newswire, Sep 24
- ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary DutySupply Chain Digital, Sep 23
- ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATIONGlobeNewswire, Sep 22
- Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015GlobeNewsWire, Sep 22
- Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential ClaimsGlobeNewsWire, Sep 21
Erasca peers
Erasca’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Erasca stock FAQ
What is Erasca’s market cap?
Erasca’s market cap is $4.90B at the Sep 28, 2026 close of $14.13, with 349.8M shares outstanding.
What is the Erasca stock forecast?
The consensus analyst 12-month price target for Erasca is $24.11, +70.6% from the last close. Of the 8 firms that rated the stock in the last 90 days, 6 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Erasca stock overvalued or undervalued?
On Gekko’s estimate Erasca is undervalued: the Sep 28, 2026 close of $14.13 is 23.0% below Gekko Fair Value of $18.34. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Erasca report earnings next?
Erasca is expected to report on Nov 11, 2026 (43 days away). Analysts expect earnings of −$0.14 per share. Erasca beat the earnings estimate in 3 of its last 8 reports, moving 6.8% on average across the report.
What is Erasca’s 52-week high and low?
Erasca’s 52-week high is $24.28 and its 52-week low is $1.79; it closed at $14.13 on Sep 28, 2026, +680.7% over the past year.
Is Erasca stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Erasca the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.